Subscribe
Experts at the AVBCC 5th Annual Conference suggested that retrospective analyses of big data should more effectively differentiate between different approaches to cancer care based on care quality and evidence-based, clinically meaningful outcomes. Data silos can help in the short-term to prioritize process measures.
Combination treatment with nivolumab and ipilimumab doubled progression-free survival in patients with advanced melanoma, according to CheckMate 067 investigators.
In a decade of provider risk, the CMS Oncology Payment Models are shifting toward risk management as part of the continued evolution toward integrated networks and bundled payments in healthcare.
Elotzumab’s “double whammy” mechanism of action acts directly on the tumor itself and enhances the activity of natural killer cells to kill the tumor.
  • Palbociclib Prolongs Progression-Free Survival in Patients with Advanced Breast Cancer
  • Surveillance Imaging Not Cost-Effective in Patients with Diffuse Large B-Cell Lymphoma After First Remission
  • Bronchial Gene-Expression Classifier Improves Lung Cancer Diagnosis with Bronchoscopy
  • Serial Biomarker Measurements Double the Amount of Screening-Detected Cancers
  • Pazopanib with Depot Octreotide Has Antitumor Activity in Patients with Advanced Neuroendocrine Tumors
  • Value-Based Drug Pricing a New Target for a Large PBM Company in Its Negotiations with Pharmaceutical Companies
  • Prenatal Blood Test Can Also Detect Cancer in Pregnant Women, Potentially in Other Populations
  • Myxoma, a Virus Found in Rabbits, Prevents GVHD in Bone Marrow Transplant While Destroying Cancer Cells
  • First-in-Class Inducer of the KLF4 Gene Receives FDA Designation as Orphan Drug
Washington, DC—Genomically driven medicine has created an opportunity for value in oncology by substantially improving outcomes and quality of life for patients with advanced cancer, said Vincent A. Miller, MD, Chief Medical Officer, Foundation Medicine, Cambridge, MA, at the Fifth Annual Conference of the Association for Value­Based Cancer Care.
Washington, DC—The establishment of pathways in oncology can reduce care variation and enhance value in patient care, said Michael Kolodziej, MD, ­National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Washington, DC—Personalized medicine will become even more critical ­­as care transitions to patient-centric, outcomes-based care models. The use of real-time data, along with an increasingly advanced understanding of cancer biology, will exponentially increase the number of treatment options for patients, making personalized treatment more effective and ultimately leading to better clinical and financial outcomes.
Chicago, IL—In patients with metastatic colorectal cancer (mCRC) with liver-dominant metastases who received first-line FOLFOX (leucovorin, fluorouracil [Adrucil], and oxaliplatin [Eloxatin]) with or without bevacizumab (Avastin) plus selective internal radiation therapy (SIRT) compared with FOLFOX with or without bevacizumab, progression-free survival (PFS) in the liver was extended by 7.9 months, according to the results of the SIRFLOX trial, which were presented at the 2015 American Society of Clinical Oncology (ASCO) meeting.
Page 1 of 3
Results 1 - 10 of 22
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology